Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
R-CHOP therapy alone for limited-stage follicular lymphoma.
Tomita N, Suzuki T, Ishiyama Y, Miyashita K, Takahashi H, Numata A, Ito S, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Yamazaki E, Taguchi J, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y. Tomita N, et al. Among authors: ishiyama y. Leuk Res. 2015 Jun;39(6):582-5. doi: 10.1016/j.leukres.2015.03.008. Epub 2015 Apr 6. Leuk Res. 2015. PMID: 25866096 Clinical Trial.
Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.
Sakai R, Ohmachi K, Sano F, Watanabe R, Takahashi H, Takasaki H, Tanaka M, Hattori Y, Kimura H, Takimoto M, Tachibana T, Tanaka E, Ishii Y, Ishiyama Y, Hagihara M, Miyazaki K, Yamamoto K, Tomita N, Ando K. Sakai R, et al. Among authors: ishiyama y. Ann Hematol. 2019 Sep;98(9):2131-2138. doi: 10.1007/s00277-019-03750-7. Epub 2019 Jul 8. Ann Hematol. 2019. PMID: 31286196 Clinical Trial.
The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients.
Ishii Y, Tomita N, Tateishi U, Ishiyama Y, Yamamoto E, Hattori Y, Hagihara M, Yamazaki E, Ishigatsubo Y. Ishii Y, et al. Among authors: ishiyama y. Med Oncol. 2014 Mar;31(3):880. doi: 10.1007/s12032-014-0880-0. Epub 2014 Feb 7. Med Oncol. 2014. PMID: 24504845
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Tomita N, Takasaki H, Ishiyama Y, Kishimoto K, Ishibashi D, Koyama S, Ishii Y, Takahashi H, Numata A, Watanabe R, Tachibana T, Ohshima R, Hagihara M, Hashimoto C, Takemura S, Taguchi J, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y. Tomita N, et al. Among authors: ishiyama y. Leuk Lymphoma. 2015 Mar;56(3):725-9. doi: 10.3109/10428194.2014.931953. Epub 2014 Aug 6. Leuk Lymphoma. 2015. PMID: 24913502
Dissemination pattern of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue.
Ishii Y, Tomita N, Suzuki T, Ishiyama Y, Kishimoto K, Yamamoto E, Koyama S, Hattori Y, Nakajima Y, Motohashi K, Takasaki H, Kawasaki R, Hashimoto C, Takemura S, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y. Ishii Y, et al. Among authors: ishiyama y. Leuk Lymphoma. 2015;56(9):2750-2. doi: 10.3109/10428194.2015.1010161. Epub 2015 Mar 6. Leuk Lymphoma. 2015. PMID: 25644745 No abstract available.
Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy.
Miyashita K, Tomita N, Taguri M, Suzuki T, Ishiyama Y, Ishii Y, Nakajima Y, Numata A, Hattori Y, Yamamoto W, Miyazaki T, Tachibana T, Takasaki H, Matsumoto K, Hashimoto C, Takemura S, Yamazaki E, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y. Miyashita K, et al. Among authors: ishiyama y. Leuk Res. 2015 Aug 29:S0145-2126(15)30368-4. doi: 10.1016/j.leukres.2015.08.016. Online ahead of print. Leuk Res. 2015. PMID: 26350140
Primary uterine lymphoma: The Yokohama Cooperative Study Group for Hematology (YACHT) study.
Ishii Y, Fujisawa S, Ando T, Suzuki T, Ishiyama Y, Kishimoto K, Hattori Y, Nakajima Y, Miyazaki T, Takasaki H, Matsumoto K, Koharazawa H, Taguchi J, Fujimaki K, Sakai R, Nakajima H. Ishii Y, et al. Among authors: ishiyama y. Asia Pac J Clin Oncol. 2018 Oct;14(5):e455-e459. doi: 10.1111/ajco.13049. Epub 2018 Jul 8. Asia Pac J Clin Oncol. 2018. PMID: 29984481
[T315I positive promyelocytic crisis of chronic myeloid leukemia].
Yamamoto E, Yamazaki E, Ishiyama Y, Koyama S, Ishii Y, Hattori Y, Nakajima Y, Tachibana T, Miyazaki T, Hagihara M, Tomita N, Ishigatsubo Y. Yamamoto E, et al. Among authors: ishiyama y. Rinsho Ketsueki. 2014 Jun;55(6):692-6. Rinsho Ketsueki. 2014. PMID: 24975339 Review. Japanese.
Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy.
Nakajima Y, Tomita N, Watanabe R, Ishiyama Y, Yamamoto E, Ishibashi D, Itabashi M, Koyama S, Takahashi H, Numata A, Takasaki H, Kawasaki R, Kuwabara H, Tanaka M, Hashimoto C, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y. Nakajima Y, et al. Among authors: ishiyama y. Med Oncol. 2014 Sep;31(9):185. doi: 10.1007/s12032-014-0185-3. Epub 2014 Aug 21. Med Oncol. 2014. PMID: 25142947
205 results